Viatris (VTRS) Revenue & Revenue Breakdown
Viatris Revenue Highlights
Latest Revenue (Y)
$15.43B
Latest Revenue (Q)
$3.66B
Main Segment (Y)
Product
Main Geography (Y)
Developed Markets Segment
Viatris Revenue by Period
Viatris Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $15.43B | -5.14% |
| 2022-12-31 | $16.26B | -9.08% |
| 2021-12-31 | $17.89B | 49.73% |
| 2020-12-31 | $11.95B | 3.87% |
| 2019-12-31 | $11.50B | 0.58% |
| 2018-12-31 | $11.43B | -3.98% |
| 2017-12-31 | $11.91B | 7.50% |
| 2016-12-31 | $11.08B | 17.47% |
| 2015-12-31 | $9.43B | 22.15% |
| 2014-12-31 | $7.72B | 11.73% |
| 2013-12-31 | $6.91B | 1.66% |
| 2012-12-31 | $6.80B | 10.87% |
| 2011-12-31 | $6.13B | 12.46% |
| 2010-12-31 | $5.45B | 7.02% |
| 2009-12-31 | $5.09B | -0.87% |
| 2008-12-31 | $5.14B | 218.74% |
| 2007-03-31 | $1.61B | 28.21% |
| 2006-03-31 | $1.26B | 0.30% |
| 2005-03-31 | $1.25B | -8.82% |
| 2004-03-31 | $1.37B | 8.31% |
| 2003-03-31 | $1.27B | 14.96% |
| 2002-03-31 | $1.10B | 30.40% |
| 2001-03-31 | $846.70M | 7.16% |
| 2000-03-31 | $790.14M | 9.57% |
| 1999-03-31 | $721.10M | 36.42% |
| 1998-03-31 | $528.60M | 20.08% |
| 1997-03-31 | $440.20M | 12.04% |
| 1996-03-31 | $392.90M | -0.81% |
| 1995-03-31 | $396.10M | 57.31% |
| 1994-03-31 | $251.80M | 18.77% |
| 1993-03-31 | $212.00M | - |
Viatris generated $15.43B in revenue during NA 2023, up -5.14% compared to the previous quarter, and up 134.92% compared to the same period a year ago.
Viatris Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $3.66B | -4.38% |
| 2023-12-31 | $3.82B | -2.98% |
| 2023-09-30 | $3.94B | 0.59% |
| 2023-06-30 | $3.92B | 5.08% |
| 2023-03-31 | $3.73B | -3.79% |
| 2022-12-31 | $3.88B | -4.96% |
| 2022-09-30 | $4.08B | -0.94% |
| 2022-06-30 | $4.12B | -1.79% |
| 2022-03-31 | $4.19B | -3.45% |
| 2021-12-31 | $4.34B | -4.30% |
| 2021-09-30 | $4.54B | -0.90% |
| 2021-06-30 | $4.58B | 3.33% |
| 2021-03-31 | $4.43B | 22.27% |
| 2020-12-31 | $3.62B | 21.92% |
| 2020-09-27 | $2.97B | 8.82% |
| 2020-06-28 | $2.73B | 4.28% |
| 2020-03-29 | $2.62B | -17.94% |
| 2019-12-31 | $3.19B | 7.77% |
| 2019-09-30 | $2.96B | 3.86% |
| 2019-06-30 | $2.85B | 14.27% |
| 2019-03-31 | $2.50B | -18.94% |
| 2018-12-31 | $3.08B | 7.56% |
| 2018-09-30 | $2.86B | 1.93% |
| 2018-06-30 | $2.81B | 4.61% |
| 2018-03-31 | $2.68B | -17.12% |
| 2017-12-31 | $3.24B | 8.43% |
| 2017-09-30 | $2.99B | 0.84% |
| 2017-06-30 | $2.96B | 8.92% |
| 2017-03-31 | $2.72B | -16.78% |
| 2016-12-31 | $3.27B | 6.89% |
| 2016-09-30 | $3.06B | 19.39% |
| 2016-06-30 | $2.56B | 16.86% |
| 2016-03-31 | $2.19B | -12.02% |
| 2015-12-31 | $2.49B | -7.59% |
| 2015-09-30 | $2.70B | 13.64% |
| 2015-06-30 | $2.37B | 26.71% |
| 2015-03-31 | $1.87B | -10.13% |
| 2014-12-31 | $2.08B | -0.06% |
| 2014-09-30 | $2.08B | 13.43% |
| 2014-06-30 | $1.84B | 7.09% |
| 2014-03-31 | $1.72B | -5.14% |
| 2013-12-31 | $1.81B | 2.33% |
| 2013-09-30 | $1.77B | 3.86% |
| 2013-06-30 | $1.70B | 4.30% |
| 2013-03-31 | $1.63B | -4.16% |
| 2012-12-31 | $1.70B | -5.93% |
| 2012-09-30 | $1.81B | 6.99% |
| 2012-06-30 | $1.69B | 6.23% |
| 2012-03-31 | $1.59B | 4.00% |
| 2011-12-31 | $1.53B | -2.83% |
| 2011-09-30 | $1.58B | 0.12% |
| 2011-06-30 | $1.57B | 8.62% |
| 2011-03-31 | $1.45B | 1.01% |
| 2010-12-31 | $1.43B | 5.86% |
| 2010-09-30 | $1.36B | -0.98% |
| 2010-06-30 | $1.37B | 5.89% |
| 2010-03-31 | $1.29B | -4.40% |
| 2009-12-31 | $1.35B | 6.94% |
| 2009-09-30 | $1.26B | -0.23% |
| 2009-06-30 | $1.27B | 4.72% |
| 2009-03-31 | $1.21B | 0.56% |
| 2008-12-31 | $1.20B | -27.38% |
| 2008-09-30 | $1.66B | 37.71% |
| 2008-06-30 | $1.20B | 11.97% |
| 2008-03-31 | $1.07B | - |
Viatris generated $3.66B in revenue during Q1 2024, up -4.38% compared to the previous quarter, and up 94.34% compared to the same period a year ago.
Viatris Revenue Breakdown
Viatris Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Product | $16.22B | $17.81B | - |
| Brands | $9.89B | - | - |
| Complex GX and Biosimilars | $1.31B | - | - |
| Generics | $5.02B | - | - |
| Product and Service, Other | - | - | $126.10M |
Viatris's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (50.00%), Brands (30.49%), Generics (15.46%), and Complex GX and Biosimilars (4.05%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Generics | $1.34B | $1.23B | - | - | - | - | - | - | - | - | - | - |
| Brands | $2.31B | $2.53B | - | - | - | - | - | - | - | - | - | - |
| Xalabrands | $42.50M | $47.90M | $48.40M | $54.00M | $55.80M | $58.30M | $57.90M | - | - | - | - | - |
| Product and Service, Other | - | - | $9.10M | $10.00M | $8.90M | $10.80M | $11.40M | $13.50M | - | - | - | - |
Viatris's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Brands (62.48%), Generics (36.37%), and Xalabrands (1.15%).
Viatris Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Greater China Segment | $2.20B | - | - |
| Japan, Australia and New Zealand Segment | $1.63B | - | - |
| Emerging Markets Segment | $2.62B | - | - |
| UNITED STATES | $3.95B | $4.18B | $3.75B |
| Developed Markets Segment | $9.77B | - | - |
| CHINA | $1.95B | $1.98B | - |
| INDIA | - | - | $1.16B |
| FRANCE | - | - | $1.07B |
Viatris's latest annual revenue breakdown by geography, as of Dec 22: Developed Markets Segment (44.17%), UNITED STATES (17.84%), Emerging Markets Segment (11.83%), Greater China Segment (9.95%), CHINA (8.82%), and Japan, Australia and New Zealand Segment (7.38%).
Quarterly Revenue by Country
| Country | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emerging Markets Segment | $626.40M | - | - | - | - | - | - | - | - | - | - | - |
| Developed Markets Segment | $2.17B | - | - | - | - | - | - | - | - | - | - | - |
| Japan, Australia and New Zealand Segment | $317.80M | - | - | - | - | - | - | - | - | - | - | - |
| Greater China Segment | $543.90M | $548.40M | $1.60M | $2.20M | $100.00K | $1.90M | $1.70M | $3.40M | $2.70M | - | $1.10M | $1.00M |
Viatris's latest quarterly revenue breakdown by geography, as of Mar 24: Developed Markets Segment (59.27%), Emerging Markets Segment (17.15%), Greater China Segment (14.89%), and Japan, Australia and New Zealand Segment (8.70%).
Viatris Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company | $4.26T | $1.05T |
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| TEVA | Teva Pharmaceutical Industries | $15.85B | $4.16B |
| VTRS | Viatris | $15.43B | $3.66B |
| HLN | Haleon | $11.30B | $2.92B |
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| LNTH | Lantheus | $1.30B | $394.09M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| HCM | HUTCHMED (China) | $838.00M | $152.56M |
| TLRY | Tilray Brands | $788.94M | $188.34M |
VTRS Revenue FAQ
What is Viatris’s yearly revenue?
Viatris's yearly revenue for 2023 was $15.43B, representing a decrease of -5.14% compared to 2022. The company's yearly revenue for 2022 was $16.26B, representing a decrease of -9.08% compared to 2021. VTRS's yearly revenue for 2021 was $17.89B, representing an increase of 49.73% compared to 2020.
What is Viatris’s quarterly revenue?
Viatris's quarterly revenue for Q1 2024 was $3.66B, a -4.38% decrease from the previous quarter (Q4 2023), and a -1.94% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $3.82B, a -2.98% decrease from the previous quarter (Q3 2023), and a -1.33% decrease year-over-year (Q4 2022). VTRS's quarterly revenue for Q3 2023 was $3.94B, a 0.59% increase from the previous quarter (Q2 2023), and a -3.34% decrease year-over-year (Q3 2022).
What is Viatris’s revenue growth rate?
Viatris's revenue growth rate for the last 3 years (2021-2023) was -13.75%, and for the last 5 years (2019-2023) was 34.14%.
What are Viatris’s revenue streams?
Viatris's revenue streams in c 22 are Product, Brands, Complex GX and Biosimilars, and Generics. Product generated $16.22B in revenue, accounting 50.00% of the company's total revenue, down -8.96% year-over-year. Brands generated $9.89B in revenue, accounting 30.49% of the company's total revenue Complex GX and Biosimilars generated $1.31B in revenue, accounting 4.05% of the company's total revenue Generics generated $5.02B in revenue, accounting 15.46% of the company's total revenue
What is Viatris’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Viatris was Product. This segment made a revenue of $16.22B, representing 50.00% of the company's total revenue.